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Abstract
Hereditary lower motor neuron diseases (LMND) other than 5q‐spinal muscular
atrophy (5q‐SMA) can be classified according to affected muscle groups. Proximal
and distal forms of non‐5q‐SMA represent a clinically and genetically hetero-
geneous spectrum characterized by significant overlaps with axonal forms of
Charcot–Marie–Tooth (CMT) disease. A consensus for the best approach to mole-
cular diagnosis needs to be reached, especially in light of continuous novel gene
discovery and falling costs of next‐generation sequencing (NGS). We performed
exome sequencing (ES) in 41 families presenting with non‐5q‐SMA or axonal CMT,
25 of which had undergone a previous negative neuromuscular disease (NMD) gene
panel analysis. The total diagnostic yield of ES was 41%. Diagnostic success in the
cohort with a previous NMD‐panel analysis was significantly extended by ES, pri-
marily due to novel gene associated‐phenotypes and uncharacteristic phenotypic
presentations. We recommend early ES for individuals with hereditary LMND
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presenting uncharacteristic or significantly overlapping features. As mitochondrial
dysfunction was the underlying pathomechanism in 47% of the solved individuals,
we highlight the sensitivity of the anterior horn cell and peripheral nerve to mi-
tochondrial imbalance as well as the necessity to screen for mitochondrial disorders
in individuals presenting predominant lower motor neuron symptoms.
K E YWORD S
axonal CMT, exome sequencing, hereditary neuropathy, lower motor neuron disease,
mitochondrial dysfunction, non‐5q‐SMA
1 | INTRODUCTION
Hereditary lower motor neuron diseases are characterized by mus-
cular atrophy, weakness, and hyporeflexia. They can be divided into
two broad groups of genetic disorders: spinal muscular atrophies (SMA)
and distal hereditary motor neuropathies (HMNs; Garg et al., 2017).
SMA is a heterogeneous group of hereditary disorders characterized
by anterior horn cell degeneration in the spinal cord, leading to
progressive muscle weakness and atrophy. While around 96% of
SMA cases are caused by autosomal recessive (AR) deletions or
rarely point mutations in the SMN1 gene on chromosome 5q13
(5q‐SMA; Lefebvre et al., 1995; Wirth et al., 2020; Wirth, 2000), the
remaining minority form a genetically heterogeneous and phenoty-
pically diverse group of conditions summarized under the umbrella
term 'non‐5q‐SMA'. In contrast to clinically well‐characterized SMA
cases, in the routine diagnostic labs only about 50% of individuals
suspected to have SMA were found with biallelic SMN1 mutations
(Karakaya et al., 2018). These groups of heterogeneous hereditary
disorders (non‐5q‐SMAs) share neither an inheritance pattern nor a
common underlying pathomechanism and often present a more
complex phenotype with variable onset and features beyond the
classical 5q‐SMA spectrum (Peeters et al., 2014; Rossor et al., 2012).
A classification system typically deployed is by muscle involvement
pattern, distinguishing between proximal predominant and distal
predominant forms (Darras, 2011).
Both proximal and distal non‐5q‐SMAs show phenotypic and
genetic overlap with other neuromuscular disorders (NMD) including
amyotrophic lateral sclerosis (ALS), hereditary spastic paraplegias
(HSP), and Charcot–Marie–Tooth (CMT) disease (Peeters
et al., 2014; Rossor et al., 2012). Especially axonal forms of CMT
significantly overlap with distal non‐5q‐SMA or HMN, as for both
phenotypes clinical presentation and electrophysiological findings
are characteristic of a length‐dependent axonal motor neuropathy,
the distinguishing feature being the additional involvement of the
F IGURE 1 Study and cohort characterization. (a) Overview of the clinical spectrum in focus. Proximal and distal non‐5q‐SMAs show
significant genetic and phenotypic overlap with axonal CMT. (b) Clinical, demographic data and prior testing strategy of affected individuals.
AD, autosomal dominant; AR, autosomal recessive; CMT, Charcot–Marie–Tooth; 5q‐SMA, 5q‐spinal muscular atrophy; XLR, X‐linked recessive
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sensory nerves in axonal CMT (Irobi et al., 2006; Rossor et al., 2012).
However, as HMN can present with minor sensory involvement, and
axonal CMT can show motor‐predominance, the disorders represent
two ends of a continuous phenotypic spectrum rather than two
distinct disease entities (Figure 1(a); Bansagi et al., 2017; Rossor
et al., 2012), a fact further highlighted by the many shared
causal genes such as GARS1 (Antonellis et al., 2003), TRPV4
(Auer‐Grumbach et al., 2010), or HSPB1 (Evgrafov et al., 2004).
In addition, also proximal predominant non‐5q‐SMA and axonal CMT
are allelic disorders, such as in the case of TRPV4 (Auer‐Grumbach
et al., 2010) or DYNC1H1 (Harms et al., 2012; Weedon et al., 2011).
Since the introduction of next‐generation sequencing (NGS) into
research and molecular diagnostics, the number of genes associated
with axonal motor‐ and sensorimotor neuropathies has grown im-
mensely and continuously (Benarroch et al., 2019; Garg et al., 2017).
However, while the rising number of detected disease‐genes enables
a definite molecular diagnosis for an increasing number of affected
individuals, it has also created novel challenges, a prominent one
being the question of the best approach to molecular diagnosis
(Volk & Kubisch, 2017). The need for cost‐ and analysis‐efficiency
often clashes with the necessity for fast‐track diagnosis and high
diagnostic yield, which is essential to prevent the infamous 'diag-
nostic odyssey'. As gene panels covering a large number of asso-
ciated disease‐genes allow a cost‐efficient and phenotype‐centric but
still comprehensive approach, they have become the diagnostics
method of choice for heterogeneous lower motor neuron disorders
in the last years (Garg et al., 2017). However, the narrowing price‐
gap between targeted panel sequencing and exome sequencing (ES)
(Mazzarotto et al., 2020) as well as evidence supporting the reduc-
tion of incremental costs and time‐to‐diagnosis by early ES analysis
(Soden et al., 2014; Stark et al., 2017) increasingly support an early,
maybe even first‐tier, unbiased and comprehensive ES approach for
disorders with clinical and genetic heterogeneity. Thus, continuous
testing and critical comparison of the diagnostic methods are es-
sential for providing time‐ and cost‐effective high‐yield molecular
diagnostics in the fastly evolving field of NMD genetics.
In a previous study, we developed and tested a large neuro-
muscular disease gene panel comprising 479 genes (subsequently
referred to as NMD‐panel; Karakaya et al., 2018). Among the 479
NMD‐associated genes, 127 genes were associated with motor
neuron disorders and hereditary neuropathies, 79 genes for her-
editary paraplegias and ataxias (excluding repeat expansion‐
associated genes), 190 genes for muscular dystrophies, myopathies
and myasthenic syndromes, 83 genes for arthrogryposis syndromes,
other neuromuscular diseases and candidate disease‐associated
genes. A detailed list of the genes in the NMD panel can be found
in our previous study (Karakaya et al., 2018). Seventy‐four in-
dividuals with a clinical presentation of either proximal or distal non‐
5q‐SMA or axonal CMT were analyzed via the NMD‐panel, with a
total diagnostic yield of 45% (33% for non‐5q‐SMA, 65% for axonal
CMT) (Karakaya et al., 2018). In the present study, we re‐evaluated
25 cases with a previous negative NMD‐panel analysis using ES.
We additionally performed ES analysis on 16 cases without prior
NMD‐panel analysis. We compared ES diagnostic yield in the
NMD‐panel and no‐NMD‐panel cohort to establish the significance
of extended panel diagnostics compared to the expanded unbiased
ES approach in rare hereditary lower motor neuron phenotypes. By
identifying disease‐associated genes not included in the NMD‐panel,
we aimed to uncover common reasons for panel escaping to facilitate
panel upgrading, in turn increasing diagnostic yield and further im-
proving time‐ and cost‐efficiency in NMD diagnostics. Studies in
recent years provided important insights for hereditary neuropathies,
in which the cellular defects and their underlying molecular patho-
mechanisms were unraveled (Beijer et al., 2019). We, therefore, in-
vestigated the cellular processes that were impaired by the detected
mutations in our cohort and observed mitochondrial dysfunction as a
frequent pathomechanism involved in rare disorders of the anterior
horn cell and/or peripheral nerve.
2 | MATERIALS AND METHODS
2.1 | Editorial policies and ethical considerations
This study conformed to standards outlined in the Declaration of
Helsinki and was approved by the Ethics Committee of the
University of Cologne (Reference Number 13‐022). Informed written
consent for the collection of human material, for the participation in
the study, and for publication purposes was obtained from the re-
spective subjects or their legal guardians following the regulations of
the Ethics Committee of the University of Cologne.
2.2 | Proband selection
Forty‐one independent individuals presenting with LMND pheno-
type with or without sensory involvement, with a suspected clinical
diagnosis of either non‐5q‐SMA (n = 25) or axonal CMT (n = 16) and
103 family members were selected for the study. The ethnicities of
the recruited probands were Turkish (n = 21), Iranian (n = 8),
German (n = 7), Moldavian (n = 1), Arabic (n = 1), Russian (n = 1),
Russian/Belarussian (n = 1), and Turkmen (n = 1). Twenty‐five (61%)
were selected after inconclusive NMD‐panel analysis comprising
479 genes implicated in neuromuscular disease (Karakaya
et al., 2018), either on a research basis as part of the NeurOmics‐
LMND study (n = 18) (Karakaya et al., 2018) or on diagnostic basis
as part of the diagnostic routine of the Institute of Human Genetics
of the University Hospital of Cologne (n = 7). The remaining 16 in-
dividuals (39%) were recruited for ES without prior NMD‐panel
testing but with previous negative phenotype‐specific genetic
testing (Figure S2). At minimum, homozygous SMN1 deletions were
excluded before selection in all cases. Each affected individual was
phenotypically characterized based on a questionnaire that was
originally established for the NeurOmics research study (Karakaya
et al., 2018) and later on adopted for the current study and re‐
approved by the Ethics Committee of the University of Cologne.
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The questionnaire included information about the age at onset,
family history, parental consanguinity, developmental data (for
index probands <5 years), findings of physical and neurological
examination, investigation findings (electromyography, nerve con-
duction studies, muscle biopsy/MRI, cranial/spinal MRI) and
laboratory results.
2.3 | Exome sequencing
ES was conducted for 32 parent‐child trios, two parent‐child duos,
and seven singletons. For target enrichment, we used the SureSelect
All Exon v7 kit (Agilent) according to the 'SureSelectXT Low Input
Automated Target Enrichment for Illumina Paired‐End Multiplexed
Sequencing' protocol (Version D0, July 2018) provided by Agilent
Technologies. Sample processing steps were automated using the
NGS Workstation Option B (Agilent), deploying the reagents speci-
fied in the protocol. Before target enrichment via hybridization‐
based capture, an individual molecular‐barcoded and indexed library
was prepared for each sample. Input samples contained 10–200 ng
genomic DNA. After DNA fragmentation to a size of 150–200 base‐
pair (bp) and DNA end‐modification including end‐repair, dA‐tailing,
and ligation of the molecular‐barcoded adaptor, adaptor‐ligated
libraries were amplified via PCR using index primers. Amplified DNA
was subsequently purified using AMPure XP beads (Beckman Coul-
ter). After quantity and quality assessment (Agilent tape station), the
prepared and aliquoted gDNA library was hybridized to the target‐
specific SureSelect Capture Library via thermal cycler incubation.
The gDNA‐Capture Library hybrids were then captured with
streptavidin‐coated magnetic beads. Postcapture, SureSelect‐
enriched DNA samples were PCR‐amplified and purified. After
library validation and quantification (Agilent tape station), equimolar
amounts of the library were pooled. Pools were quantified by using
the Peqlab KAPA Library Quantification Kit and the Applied Bio-
systems 7900HT Sequence Detection System and sequenced by
using a paired‐end 100‐nucleotide protocol on the Illumina Nova-
Seq6000 sequencer, with a resulting average 75× target coverage.
2.4 | Alignment and variant calling
Reads were aligned to human reference genome hg38/GRCh38
(Genome Reference Consortium Human GRCh38). For read im-
provement, PCR duplicates were removed using Picard tools, and
local realignment and base quality score recalibration (BQSR) were
performed using Genome Analysis Toolkit (GATK). Single nucleotide
polymorphisms (SNPs) and short insertions/deletions (INDELs) were
called by Platypus, Haplotype Caller, and Mpileup programs and
subsequently filtered via variant quality score calibration (VQSR)
using GATK. For CNV detection based on coverage analysis XHMM,
Conifer, and ExomeDepth algorithms were applied. ALLEGRO pro-
gram was used for ROH detection based on multipoint linkage ana-
lysis. Data combining and functional variant annotation were enabled
by the COMBINE and FUNC modules developed by Cologne Center
for Genomics (CCG).
2.5 | Variant interpretation and classification
ES data was analyzed using exome analysis pipeline Varbank 2.0
developed by CCG. We focused our analysis on single nucleotide
nonsynonymous missense, loss‐of‐function, and splice site variants,
as well as short INDELs. Parental consanguinity analysis was esti-
mated by the total sum of runs of homozygosity (ROH) in the af-
fected individual (>100 Mb) and the average allele sharing
percentage between parents (>10%). After application of a first fil-
tering step to select variants based on inheritance pattern via the
'allele read frequency' (frequency of the allele carrying reads with
the detected variant compared to the reference carrying reads in %:
75%–100% for homozygous variants: 25%–75% for heterozygous
variants), and allele frequency (<1% for recessive variants, <0.1% for
dominant variants), variants were evaluated utilizing the genomic
variant search engine 'VarSome' (Kopanos et al., 2019), Human Gene
Mutation Database (HGMD) Professional 2019.4, Database of Single
Nucleotide Polymorphisms and ClinVar archive (latest accessions in
August 2020). For a comprehensive and integrated approach to
computational in silico pathogenicity prediction, we applied the
Varbank 2.0 'MedPred', a median rank score incorporating the pre-
diction scores of up to 31 in silico mutation pathogenicity prediction
algorithms (value between 0 and 1; 0 = benign; 1 = pathogenic; -
Table S3). Following the ACMG 2015 guidelines (Richards
et al., 2015), we classified the variants as pathogenic (class 5), likely
pathogenic (class 4), or uncertain significance (class 3). For a final
variant validation and confirmation of segregation, candidate var-
iants were resequenced via the Sanger method on an ABI 3730XL
sequencing machine (Sanger et al., 1977). For probands with an in-
conclusive SNV/INDEL analysis, we investigated copy number var-
iations (CNVs) utilizing Integrative Genomics Viewer (IGV) software
(Broad Institute) and Varbank's gene coverage tool in compliance
with the results yielded from CNV detection based on coverage
analysis.
3 | RESULTS
3.1 | Cohort of affected individuals
Forty‐one independent individuals (28 males, 13 females) with a
suspected diagnosis of LMND were selected for ES. We included
25 individuals (61%) with a suspected clinical diagnosis of proximal or
distal non‐5q‐SMA and 16 individuals (39%) presenting with features
consistent with axonal (or in two cases intermediate) CMT. Clinical
presentation was not only of variable onset and severity but in some
cases overlapping with other neuromuscular or neurologic pheno-
types, as to be expected in a clinically heterogeneous spectrum such
as non‐5q‐SMA. A majority of individuals (n = 37, 90%) had an onset in
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pediatric or adolescent age (<18 years), while only four subjects (10%)
presented with an adult‐onset disorder (Figure 1(b)).
Of the 41 families, 23 had an inheritance pattern suggestive of
autosomal‐recessive (AR), one of autosomal‐dominant (AD), one of
X‐linked (XLR) inheritance, and 13 were sporadic cases. The inheritance
pattern in three families was ambiguous. Parental consanguinity was
present in 44% of families (28% of families in the non‐5q‐SMA cohort,
69% of families in the CMT cohort; Figure 1b). There was no
information about parental inbreeding for two individuals. However, a
total ROH sum of 128 Mb and 7% of allele sharing between parents
indicated a mild degree of inbreeding in one individual, while a low
ROH summary of 44 Mb and an allele sharing percentage between
parents of 2% favored nonconsanguinity in the second.
After negative NMD‐panel analysis (n = 25; 61%) or only
phenotype‐specific genetic testing (n = 16; 39%), affected individuals
were subjected to ES. A prior panel analysis was performed for 52%
of non‐5q‐SMA and 75% of axonal CMT individuals. We performed
trio ES for individuals where the DNA samples of both biological
parents were available. Otherwise, affected individuals were se-
lected for proband‐parent duo or singleton ES. In total, ES was
performed for 107 individuals: 32 trios, two duos, and seven
singletons.
3.2 | Results and diagnostic yield of exome
sequencing analysis
ES analysis yielded a molecular diagnosis in 17 of the 41 families
(41%). Table 1 provides an overview of the affected individuals that
received a definite genetic diagnosis. Pedigrees and detailed clinical
information of the individuals with positive results are provided in
the supplementary materials (Figure S1 and Table S1). According to
ACMG 2015 guidelines (Richards et al., 2015), the identified variants
included ten pathogenic and ten likely pathogenic variants (Table 1).
One variant in SEPSECS was annotated as a variant of uncertain
significance (VUS) following ACMG criteria but considered putatively
disease‐causing; it was detected in trans with a pathogenic variant
and affecting the tRNA interaction site of the protein. Moreover,
VUS were detected in five additional individuals (Table S2). A VUS of
particular interest is a homozygous 6bp duplication in EGR2
(NM_001136178.1: c.906_911dup) leading to the insertion of two
additional alanine molecules into an alanine stretch spanning re-
sidues 300–309 (p. Ala308_Ala309dup), which we detected in an
individual with a clinical presentation resembling EGR2‐related AR
congenital hypomyelinating neuropathy 1 (CHN1; MIM# 605253).
EGR2 has not previously been linked to the spectrum of polyalanine
expansion disorders and ACMG guidelines annotated the variant
only as a VUS. Additionally of note is the identification of compound‐
heterozygous VUS in MACF1 in three unrelated affected individuals
in our cohort (Table S2), which we consider worth remarking due to
previous associations of MACF1 with a to‐date not securely estab-
lished NMD phenotype (Jorgensen et al., 2014; Kang et al., 2019).
Nineteen families remained unsolved, in four of which we detected
putative variants in genes that we regard as novel disease‐associated
candidates. These have been added to the GeneMatcher database
and will be followed in future studies. RefSeq identification numbers
of each gene with pathogenic/likely pathogenic variants or VUS are
given in the footnote of the corresponding table (Table 1 and
Table S2).
Sixteen of the solved cases showed a recessive pattern (12
homozygous, four compound‐heterozygous variants), and one de
novo variant was found in a sporadic case. Of the overall 21 detected
variants, 12 were known pathogenic variants, whereas nine were
novel variants not previously published (Table 1).
Diagnostic yield in consanguineous families (50%) was higher than
in remaining nonconsanguineous or ambiguous families (35%). Com-
paring non‐5q‐SMA with axonal CMT individuals, we were able to
solve seven of the 25 individuals with a suspected clinical diagnosis of
non‐5q‐SMA and 10 of the 16 axonal CMT individuals, adding up to
diagnostic yields of 28 and 63%, respectively. The significantly higher
diagnostic yield in the CMT cohort correlates with the higher number
of consanguineous families in this group (69% consanguineous families
in the CMT cohort vs. 28% in the non‐5q‐SMA cohort). Of the seven
solved individuals with a suspected diagnosis of non‐5q‐SMA, two had
a variant in known SMA‐phenotype associated genes (AGTPBP1,
EXOSC3). Of the 10 individuals with axonal CMT with a positive result,
only three had variants in genes causing a characteristic pure axonal
CMT phenotype (PDXK,MPV17, SPG11). Thus, 12 of the 17 individuals
with a positive ES analysis received a molecular diagnosis, not in line
with the initial clinical diagnosis (Table 1).
3.3 | Comparison of ES outcome post‐NMD‐panel
versus without NMD‐panel analysis
A definite diagnosis by ES was achieved for 10 of the 25 individuals
with a previous negative NMD‐panel analysis (three non‐5q‐SMA
and seven axonal CMT cases) and for seven of the 16 individuals
without prior NMD‐panel testing (four non‐5q‐SMA and three axonal
CMT cases), amounting to diagnostic yields of 40% and 44%,
respectively.
Of the seven ES‐detected variants in the cohort without prior
NMD‐panel testing, four were located in genes included in our
NMD‐panel (57%), which we therefore categorized as 'NMD‐panel‐
detectable': POLG (AR mitochondrial ataxia syndrome; MIM#
607459), SPG11 (AR spastic paraplegia 11; MIM# 604360), C12orf65
(AR spastic paraplegia 55; MIM# 615035), and EXOSC3 (AR ponto-
cerebellar hypoplasia type 1B; MIM# 614678). Of the 10 diagnosed
cases in the cohort with prior NMD‐panel testing, two causal var-
iants were located in NMD‐panel genes (20%): NDUFS6 (AR mi-
tochondrial complex I deficiency nuclear type 9; MIM# 618232) and
TTN (AR limb‐girdle muscular dystrophy 10; MIM# 608807). The
homozygous variant in NDUFS6 (Table 1) had in fact been detected in
the prior panel analysis, yet had been annotated as a VUS because of
uncharacteristic clinical presentation of a known pathogenic variant,
and ES was performed as a more comprehensive method, which did
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not reveal any other causal variants and therefore consolidated the
molecular diagnosis. The compound‐heterozygous variants in TTN
had remained undetected by panel analysis due to the missed call of
a heterozygous 54 bp deletion by the calling algorithm of the NMD
panel. This 54 bp deletion was later detected by ES. Altogether, of
the 17 ES‐detected disease‐causing variants, six were 'NMD‐panel‐
detectable' (gene included in NMD‐panel) (35%) while 11 variants
were not (65%; Figure S3).
We evaluated the reasons for prior noninclusion of detected
genes in the NMD‐panel to uncover the most frequent reasons for
missed panel diagnosis. Our analysis showed that 50% (5/10) of
genes were only recently identified as associated with their re-
spective phenotypes, with first reports in the past three years:
AGTPBP1 (AR childhood‐onset neurodegeneration with cerebellar
atrophy; MIM# 618276; Shashi et al., 2018), ADPRS (AR stress‐
induced childhood‐onset neurodegeneration with variable ataxia
and seizures; MIM# 618170) (Ghosh et al., 2018), FDXR (AR optic
atrophy‐ataxia‐peripheral neuropathy‐global developmental de-
lay syndrome; ORPHA:543470; Peng et al., 2017), PDXK (AR
hereditary motor and sensory neuropathy type VIC with optic
atrophy; MIM# 618511; Chelban et al., 2019), VPS13D (AR spi-
nocerebellar ataxia 4; MIM# 607317; Gauthier et al., 2018; Seong
et al., 2018). The other half was not included due to phenotypic
discordance: ARSA (AR metachromatic leukodystrophy; MIM#
250100) was not included because of its characteristic cranial
MRI abnormalities usually leading to single‐gene testing (van
Rappard et al., 2015), DNM1L (AD/AR encephalopathy due to
defective mitochondrial and peroxisomal fission 1; MIM#
614388), ECHS1 (AR mitochondrial short‐chain enoyl‐CoA
hydratase‐1 deficiency; MIM# 616277), and SEPSECS (AR ponto-
cerebellar hypoplasia type 2D; MIM# 613811) were not included
because of clinical presentation where pure NMD features are
not typically most prominent. MPV17 (AR axonal CMT type 2EE;
MIM# 256810) was not included due to the gene's more frequent
hepatocerebral phenotype.
3.4 | Underlying pathomechanisms in solved
cases: mitochondrial dysfunction the most frequent
pathomechanism
When assessing the physiological cellular functions and related pa-
thomechanisms of the proteins affected by our detected mutations,
we found that eight of the 17 solved probands (47%) harbored
variants in genes encoding proteins with a function in mitochondrial
processes, whereas the other mutated proteins had functions in
various other physiological processes (Figure 2). Five of the eight
individuals with mitochondrial dysfunction variants belonged to the
axonal CMT cohort, while three were of the non‐5q‐SMA group. The
mechanisms impaired were mitochondrial dynamics (VPS13D,
DNM1L), mtDNA replication and maintenance (POLG, MPV17), mi-
tochondrial translation machinery (C12orf65), and respiratory chain
(NDUFS6, FDXR, ECHS1; Figure 2).
4 | DISCUSSION
In the scope of this study, we validated the diagnostic potential of ES
in a complex and clinically heterogeneous cohort of previously un-
diagnosed non‐5q‐SMA and axonal CMT individuals. In fact, drawing
clear and reliable conclusions from comparison of diagnostic yields in
the cohorts with or without prior NMD‐panel is not possible because
of the obvious small cohort evaluation bias. Especially in clinically
heterogeneous cohorts, diagnostic yield and thus NMD‐panel suc-
cess is highly dependent on the individual characteristics of the se-
lected probands. Yet, more than half of the genes detected in the
cohort without prior NMD‐panel testing were NMD‐panel‐
detectable, highlighting the diagnostic potential of the panel despite
the almost similar diagnostic yields. Our study emphasizes the need
for generous inclusion of overlapping phenotypes and constant panel
updating when applying panel diagnostics to lower motor neuron
disorder phenotypes, which is especially important in countries
where only gene panels are routinely performed due to reimburse-
ment policies.
The obvious advantages of ES in the diagnosis and re-
search of Mendelian disorders have been outlined thoroughly
(Gilissen et al., 2011; Rabbani et al., 2012; Rabbani et al., 2014;
Warr et al., 2015). In this regard, during the course of our study,
we were able to highlight the potential significance of time‐
efficient genetic diagnosis provided by early ES in a rare case of a
treatment opportunity for peripheral neuropathy with optic
atrophy (Keller et al., 2020).
When it comes to deciding whether to perform gene panel
testing or direct ES, suspected clinical diagnosis and individual phe-
notype characteristics should be considered as the key decision
factors. In a previous study, we compared the diagnostic yield of our
NMD‐panel for non‐5q‐SMA and axonal CMT and observed a sig-
nificantly higher diagnostic yield of 65% for the latter compared to
33% for non‐5q‐SMA (Karakaya et al., 2018). Although also pre-
senting significant clinical variability, CMT is mostly characterized by
its genetic variety and typically presents with the characteristic
clinical features of a length‐dependent sensorimotor neuropathy and
only limited overlaps, mainly with the dHMN (Bansagi et al., 2017;
Morena et al., 2019). Consequently, this often enables a reliable
clinical diagnosis, which then only needs to be confirmed by genetic
analysis. Thus, for individuals presenting a typical CMT phenotype
with signs of sensorimotor axonal neuropathy on NCS, a panel ap-
proach can be considered comprising all significantly overlapping
phenotypes, especially including the dHMN spectrum. However,
CMT might manifest itself as a predominant or early feature of more
complex phenotypes, of which the causal genes might be outside the
scope of the diagnostic gene panel. This is supported by the fact that
among 10 individuals with axonal CMT who were solved by ES, only
two of them could have been solved by our NMD panel. Therefore,
when presenting atypical features, a direct ES approach should be
considered. Accordingly, due to the extreme clinical heterogeneity,
first‐tier ES is highly recommended for probands who received a
clinical SMA diagnosis after initial SMN1 exclusion. In the clinical
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setting of our institution, we have observed that since the recent
advent of therapeutic options for 5q‐SMA (Nusinersen and gene
replacement therapy; Finkel et al., 2016; Mendell et al., 2017), clin-
icians opt testing for 5q‐SMA more frequently even if the clinical
phenotype does not strongly suggest a classical SMA. Naturally, this
practice would increase the number of probands classified as 'non‐
5q‐SMA' cases as well as widen the clinical spectrum observed in
these individuals. Therefore, the genetic diagnosis of the non‐5q‐SMA
group has become more essential to provide a correct diagnosis
for these probands, and only an unbiased approach such as ES
takes into account the growing range of non‐5q‐SMA‐classified
phenotypes.
In both, the solved non‐5q‐SMA and axonal CMT cohorts, mi-
tochondrial dysfunction was a frequent underlying pathomechanism.
This observation is in line with previously conducted studies on her-
editary motor‐predominant neuropathies (Bansagi et al., 2017;
F IGURE 2 Classification of the identified causal genes according to organelle pathology. Mitochondrial pathologies amount to 47% of the
overall identified disease mechanisms. †This gene was detected in two unrelated probands
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Liu et al., 2020). Naturally, the high metabolic requirements of neuronal
cells result in a high dependency on mitochondrial ATP production
through oxidative phosphorylation to uphold neuronal homeostasis and
function. As a consequence, motor neurons are extremely sensitive to
disbalances of mitochondrial physiology, and it is not surprising that
mitochondrial dysfunction is a pathological process shared by ALS
(Smith et al., 2019) and SMA (Acsadi et al., 2009; Miller et al., 2016;
Thelen et al., 2020). Many neuromuscular disorders where mitochon-
drial dysfunction is not the primary underlying defect present with
accompanying mitochondrial abnormalities (Katsetos et al., 2013), the
most notable being SMN1‐related SMA (Acsadi et al., 2009; Miller
et al., 2016; Thelen et al., 2020).
In the scope of this study, we were able to highlight the many
different mechanisms that play a role in mitochondrial pathogenesis
of LMND. Mitochondrial dynamics are essential for balanced orga-
nelle distribution, especially among the long peripheral motor and
sensory nerves. Disturbance of this dynamic process, caused mainly
by variants in MFN2 (Züchner et al., 2004) and GDAP1 (Cuesta
et al., 2002), has long been recognized as a frequent underlying pa-
thomechanism of axonal CMT. Herein, we were able to emphasize
that axonal neuropathy also presents as a predominant feature in the
remaining complex neurologic and neuromuscular spectrum caused
by mitochondrial dynamics defects, as represented in our cohort by
variants in VPS13D and DNM1L. We additionally observed impair-
ment of electron chain machinery or mitochondrial DNA synthesis as
relevant disease mechanisms presenting with prominent lower mo-
tor neuron symptoms (Figure 2).
Taking into account the entire mitochondrial disease spectrum,
peripheral neuropathy is a common (about one‐third of affected in-
dividuals; Finsterer, 2005) but rarely predominant feature (Pareyson
et al., 2013), often overshadowed by severe neurologic symptoms in-
cluding encephalopathy, epilepsy, or cerebellar ataxia (Nardin &
Johns, 2001). However, it is important to keep in mind that it can also
present as the first and/or predominant sign of a multisystem mi-
tochondrial disorder (Needham et al., 2007). Considering previous as
well as our own findings, we recommend that for individuals presenting
with prominent axonal peripheral neuropathy, especially when accom-
panied by atypical features such as ptosis, ophthalmoparesis, myopathy
or optic atrophy, mitochondrial dysfunction should be considered and
specifically tested as a potential disease cause, even when the initial
clinical presentation does not primarily suggest a mitochondrial disorder.
5 | CONCLUSIONS
Thorough phenotype characterization and constant panel‐updating
are prerequisites for successful gene panel diagnostics in genetically
heterogeneous disorders with a characteristic phenotypic presenta-
tion such as CMT. Early ES analysis should be considered in cases
with nonspecific, uncharacteristic, or overlapping phenotypic pre-
sentation such as in non‐5q‐SMA. As mitochondrial dysfunction is a
frequent pathomechanism in rare hereditary disorders of the ante-
rior horn cell and/or peripheral nerve, and mitochondriopathies can
present with peripheral neuropathy as an early or predominant
feature, genes implied in mitochondrial physiology should be given
special attention in molecular diagnosis.
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